市场调查报告书
商品编码
1473723
高通量筛选市场预测:~2030 年High Throughput Screening Market Research Report Market Forecast till 2030 |
在预测期内,高通量筛选市场规模预计将以 9.70% 的复合年增长率成长。
市场成长的因素包括基因组研究的进步、对个人化医疗日益增长的兴趣、研发投资的增加以及认知度和采用率的提高。
由于人们对个人化医疗的兴趣日益浓厚,高通量筛选市场正经历显着成长。 高通量筛选可以对大量 DNA 和 RNA 进行快速且经济高效的定序,在个人化医疗的发展中发挥着至关重要的作用。
区域见解
预计北美地区将在 2022 年拥有最大的市场占有率,达到 42.96%,亚太地区预计在预测期内成长率最大,达到 11.01%。 该市场的成长是由临床试验数量的增加和全球研发的扩张所推动的。
欧洲高通量筛选市场的成长是由 HTS 计画的推动所推动的,这些计画旨在加速新药先导分子的发现。
本报告调查了全球高通量筛选市场,提供了市场的定义和概述,分析了影响市场成长和市场机会的因素、市场规模的趋势和预测,以及依各个细分市场和地区进行的细分、竞争状况。
High Throughput Screening Market is anticipated to register a significant CAGR of 9.70% during the forecast period.
The variables adding to the development of the market are the developing genomic research exercises, rising interest for customized medication, expanding interest in innovative work, and expanding mindfulness and reception.
The high-throughput screening market is encountering significant development because of the rising interest for customized medication. Customized medication, otherwise called accuracy medication, is an inventive methodology that thinks about a singular's exceptional hereditary cosmetics, way of life, and natural variables to tailor clinical medicines and mediations. High-throughput screening, with its capacity to succession enormous volumes of DNA or RNA quickly and cost-really, assumes a crucial part in the headway of customized medication. One of the essential drivers behind the rising interest for customized medication is the developing acknowledgment that people answer diversely to medicines because of their one-of-a-kind hereditary variety. High-throughput screening empowers the ID of sickness related hereditary variations and offers bits of knowledge into the hereditary variables fundamental the viability and security of explicit treatments. By breaking down a person's hereditary data, medical care experts can decide the most appropriate therapy choices and upgrade measurements, bringing about superior patient results.
Market Segment Insights
Based on product & service, the High Throughput Screening Market has been segmented into consumables, instruments, and software & services. Based on technology, the Market has classified into cell-based assays, Lab-on-a-Chip (LOC), ultra-high-throughput screening, label-free technology, and others.
Based on application, the High Throughput Screening Market has segmented into drug discovery, biochemical screening, cell & organ-based screening, and others. In terms of end user, the Market has categorized into pharmaceutical and biotechnology companies, research institutes and organizations, and contract research organizations.
Regional Insights
North America represented the biggest market portion of 42.96% in 2022 and Asia-Pacific is projected to develop at the highest CAGR of 11.01% during the figure time frame. Moreover, market development is driven by expanding clinical preliminary numbers across the globe, and developing exploration and improvement. In addition, the underneath diagram addresses the quantity of clinical preliminaries for every region began in 2022. The market development has been driven by inorganic procedures to extend high-throughput screening (HTS) answers for measure biochemical exercises and recognize restricting associations, which speed up the timetable and lessen expenses to distinguish lead drug competitors. For example, in January 2023, Charles Waterway Research Facilities Global, Inc. (US) procured SAMDI Tech, Inc. (US), a main supplier of HTS answers for grow HTS portfolio.
The development of the European high-throughput screening market is driven by elevating HTS undertakings to speed up the revelation of a lead particle for another medication. For example, in Walk 2023, SCREENTECH opened under the correlative arrangement for biotechnology in Catalonia (Spain). This drive focused on the advancement of new ventures in view of the medication screening and medication target connection examination stage at IRB Barcelona (US).
In addition, the high guilty pleasure of high-throughput screening fire up designers like CN Bio (UK), Evosep (Denmark), Ovizio (Belgium), and Oxford Nanopore Advancements plc. (UK) through raising financing and consolidating advancement is setting out enormous open doors for the region's development.
Key Companies in the High Throughput Screening Market are Agilent Technologies Inc, Merck KGaA, Corning Incorporated, Tecan Trading AG, PerkinElmer Inc, Luminex Corporation, Beckman Coulter Inc, Hoffmann-La Roche Ltd, Promega Corporation, Hamilton Company, and Others.